Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 18, 2010

Lonza and CPRI Ally on Peptide Manufacturing and Development Services

  • Lonza and California Peptide Research (CPRI) are joining forces to more effectively serve customers requesting peptide manufacturing and development services. CPRI’s high-quality small-scale services will complement Lonza's capabilities in custom cGMP peptide manufacturing and development.

    The alliance aims at providing customers with a more complete offering that spans research through to commercial supply. It will also enable a seamless transition of custom peptide projects between CPRI’s small-scale facility and Lonza’s cGMP facilities.

    Based in San Franciscon, CPRI's customer base in North America will add to Lonza's existing facilities in Braine-l'Alleud (Belgium), Visp (Switzerland), Nansha (China), and Kourim (Czech Republic).



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »